Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Liver Cancer treatment details. Biologic therapy. Kinki University School of Medicine, Osaka-Sayama, Japan

Survival: 29.7 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: Japan
City/State/Province: Osaka-Sayama
Hospital: Kinki University School of Medicine
Journal: Link
Date: 9/2011

This phase III involved 229 hepatocellular carcinoma (HCC) patients who had been previously treated with epirubicin, cisplatin, doxorubicin, and/or mitomycin. The median patient age was 69 years and 76% were male.

Patients were treated with the biologic therapy agent called sorafenib, which is a kinase inhibitor that interferes with cancer cell growth.

The most severe adverse events were of grade 4 and included liver chemistry effects and thrombocytopenia. Hand-foot skin reactions, alopecia, diarrhea, and hypertension were also reported.

The reported median overall survival was 29.7 months.

This study was funded by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals.

Correspondence: Dr. Masatoshi Kudo; email:

E-mail to a Friend Email Physician More Information